Background {#Sec1}
==========

Tumor necrosis factor inhibitor therapy for rheumatoid arthritis (RA) patients reduces disease activity and improves function. Adalimumab (ADA) is a tumor necrosis factor inhibitor with well-established efficacy \[[@CR1], [@CR2]\]. Factors that predict RA remission with ADA treatment include concomitant use of methotrexate (MTX), no prior use of biologic disease-modifying antirheumatic drugs (DMARDs) \[[@CR3]\], negative anti-citrullinated protein antibody (ACPA), low 28-joint disease activity score with erythrocyte sedimentation rate (DAS28-ESR), no erosion, and low disability index of the health assessment questionnaire (HAQ-DI) \[[@CR4]\]. However, little is known about the factors that correlate with the continuation of remission. In addition, clinical response to ADA is dependent on ethnicity; therefore, the clinical course of Japanese patients after remission may be very different to those reported for other populations \[[@CR5]\].

We attempted to identify factors associating with sustained remission and continuation of sustained remission in RA patients treated with ADA.

Methods {#Sec2}
=======

Study design and patients {#Sec3}
-------------------------

This study was a single center, retrospective cohort study. RA patients who started ADA treatment at our institution between July 2008 and April 2014 were enrolled. All patients satisfied the classification criteria of the American College of Rheumatology \[[@CR6]\]. Patient information was obtained by retrospective analysis of medical records.

Clinical efficacy {#Sec4}
-----------------

Disease activity was assessed using DAS28-ESR \[[@CR7]\]. We defined sustained remission as a DAS28-ESR\< 2.6 that was maintained for more than 6 months, and compared the background characteristics of those who did and did not achieve sustained remission. We separated the sustained remission group into two subgroups: patients who maintained remission until the end of the observation period (defined as continuation of sustained remission) and those who experienced RA flare. Differences between these two subgroups were evaluated. The end of the observation period was defined as the period up until ADA was discontinued or the last observation (November 2014). Functional disability was assessed using HAQ-DI \[[@CR8]\].

Statistical analysis {#Sec5}
--------------------

The baseline characteristics of patients were summarized as mean, standard deviation (SD), and median. Demographic and baseline characteristics were analyzed using the Wilcoxon rank-sum test for continuous variables and the chi-square test for categorical variables. Significant variables in univariate models were included in multivariate models to identify factors that correlated with sustained remission rate. The presence of a statistically significant difference in disease activity was analyzed using the one-way analysis of variance. JMP® (SAS Institute Inc.) was used for statistical analysis.

Results {#Sec6}
=======

Baseline characteristics {#Sec7}
------------------------

A total of 122 RA patients were administered ADA between July 2008 and April 2014. Of the 122 patients, 7 received 80 mg of ADA every other week during therapy and 115 received 40 mg of ADA. Baseline demographics and disease characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Mean age ± SD of the 122 patients was 56.9 ± 16.3 years and the majority were women (81.1%). Mean body weight was 53.8 ± 10.5 kg and mean disease duration was 8.2 ± 9.4 years. Distribution of disease activity (DAS28-ESR) was as follows: high (5.1 \<): 30 cases, moderate (3.2 \< DAS ≤ 5.1): 68 cases, low (≤ 3.2): 12 cases, and not applicable: 12 cases. Mean baseline DAS28-ESR score was 4.48 ± 1.24 and HAQ-DI score was 0.95 ± 0.80. In total, 101 (82.8%) patients received concomitant MTX at a mean dose of 9.8 ± 3.1 mg/week and 36 (29.5%) received concomitant prednisolone at a mean dose of 5.0 ± 2.8 mg/day at the beginning of ADA treatment. Of the 122 patients, 87 (71.3%) were naïve to biological DMARD treatment, while 35 (28.7%) had received biological DMARDs prior to ADA. Of the latter 35 patients, 10 had received more than 2 biological DMARDs, and 21, 19, 7, and 5 patients had received infliximab, etanercept, tocilizumab, and ADA, respectively. Among five patients, in two patients ADA was used as a clinical trial before this study period. After ADA was stopped, then ADA was restarted in the observation period of this study. In another three patients, ADA was used two times in different period in this study.Table 1Baseline characteristics of patientsVariableTotal (*n* = 122)Female, *n* (%)99 (81.1)Age, years56.9 ± 16.3 (59.0)Weight, kg53.8 ± 10.5 (52.0)Disease duration, years8.2 ± 9.4 (4.0)DAS28-ESR4.48 ± 1.24 (4.29)Tender joint count3.6 ± 4.7 (2)Swollen joint count5.2 ± 4.3 (4)Physician's VAS35.5 ± 21.3 (30)Patient's VAS40.2 ± 25.3 (36.5)ESR, mm/h47.2 ± 35.6 (41)CRP, mg/dL1.55 ± 2.14 (0.53)RF-positive, *n* (%)84 (68.9)ACPA-positive, *n* (%)77 (73.3)Stage I/II/III/IV, %25.4/37.3/2.5/34.7HAQ-DI0.95 ± 0.80 (0.75)MTX use, *n* (%)101 (82.8)MTX dose, mg/week9.8 ± 3.1 (10.0)Oral steroid use, *n* (%)36 (29.5)Oral steroid dose, mg/day5.0 ± 2.8 (5.0)Prior use of biologics, *n* (%)35 (28.7)Data are mean ± SD (median) unless otherwise indicated*DAS* disease activity score, *ESR* erythrocyte sedimentation rate, *RF* rheumatoid factor, *ACPA* anti-citrullinated protein antibody, *HAQ-DI* Health Assessment Questionnaire Disability Index, *MTX* methotrexate

Evaluation of baseline factors associating with sustained remission {#Sec8}
-------------------------------------------------------------------

The proportion of patients who received concomitant MTX treatment was significantly higher in the patient group that achieved sustained remission compared to the group that did not. In contrast, age, disease duration, DAS28-ESR and HAQ-DI at baseline, the proportion of patients on concomitant prednisolone, and the proportion of patients with a history of prior use of biologics were higher in the patient group that did not achieve sustained remission compared to the group that did (Table [2](#Tab2){ref-type="table"}). Multivariate analysis showed that prior use of biologics was significantly associated with the achievement of sustained remission (Table [3](#Tab3){ref-type="table"}).Table 2Baseline characteristics correlated with sustained remissionVariableSustained remission (*n* = 39)No sustained remission (*n* = 83)*P* valueFemale, *n* (%)34 (87.2)65 (78.3)0.24Age, years50.3 ± 18.8 (53.0)60.1 ± 14.0 (62.0)0.0067Weight, kg52.9 ± 9.1 (51.5)54.2 ± 11.2 (53.0)0.70Disease duration, years4.9 ± 7.2 (1.8)9.8 ± 10.0 (7.0)0.0061DAS28-ESR at baseline4.12 ± 0.88 (4.09)4.68 ± 1.37 (4.48)0.014RF-positive, *n* (%)25 (64.1)59 (71.1)0.44ACPA-positive, *n* (%)26 (72.2)51 (73.9)0.85Presence of bone erosion, *n* (%)26 (68.4)63 (77.8)0.27HAQ-DI at baseline0.63 ± 0.69 (0.38)1.16 ± 0.82 (1.00)0.0009MTX use, *n* (%)38 (97.4)63 (75.9)0.0033Oral steroid use, *n* (%)6 (15.4)30 (36.1)0.019Prior use of biologics, *n* (%)3 (7.7)32 (38.6)0.0004Data are mean ± SD (median) unless otherwise indicated*DAS* disease activity score, *ESR* erythrocyte sedimentation rate, *RF* rheumatoid factor, *ACPA* anti-citrullinated protein antibody, *HAQ-DI* Health Assessment Questionnaire Disability Index, *MTX* methotrexateTable 3Multivariate logistic regression analysis of baseline characteristics associated with sustained remissionVariableχ2*P* valueAge, years3.00.84Disease duration, years0.790.37DAS28-ESR at baseline1.010.31HAQ-DI at baseline1.480.22MTX dose, mg weekly0.260.61PSL dose, mg daily0.730.39Prior use of biologics5.70.017*DAS* disease activity score, *ESR* erythrocyte sedimentation rate, *HAQ-DI* Health Assessment Questionnaire Disability Index, *MTX* methotrexate

Evaluation of factors that correlated with the continuation of sustained remission {#Sec9}
----------------------------------------------------------------------------------

Of the 39 patients who achieved sustained remission, 4 discontinued ADA because of sustained remission, 22 continued sustained remission and treated with ADA until the end of the observation period (mean ± SD, 27.8 ± 18.6 months; median, 20.5 months), 7 experienced RA flare (2 switched from ADA to other biologic DMARDs and 5 continued ADA), and 6 discontinued ADA because of reasons other than remission (2 because of pregnancy, 2 because of a change of hospital, 1 because of cerebral infarction, and 1 because of patient request). The patient subgroup that experienced RA flare had higher DAS28-ESR at the time of achievement of remission compared to the group that continued sustained remission (Table [4](#Tab4){ref-type="table"}). Similarly, the subgroup of patients who experienced RA flare had higher DAS28-ESR throughout the observation period compared with the subgroup that continued sustained remission (Fig. [1](#Fig1){ref-type="fig"}). Regarding MTX dose, dose at achievement of remission showed no significant change between two groups (Table [4](#Tab4){ref-type="table"}). In the seven patients of flare, mean MTX dose at flare up was 7 mg/week (range 0--15). In two patients, MTX was stopped due to side effects. (One was due to lymphoproliferative disorder, and another was due to liver dysfunction and aphthous ulcer.) Among another five patients, in one case, mean MTX dose at flare up was markedly reduced from 16 to 4 mg/week. In another four cases, MTX dose at flare up was not markedly reduced. This observation may indicate that reduction of MTX dose after remission becomes a potential risk factor of flare up. Regarding corticosteroid, in the seven patients of flare, in only a patient, dose reduction of corticosteroid (5 to 0 mg/day as predonisolone) was observed. Another one patient had no change (2 mg/day as predonisolone). The remaining five patients did not use corticosteroid. Elongation of treatment interval of ADA was not confirmed in the seven patients.Table 4Factors associated with the continuation of sustained remissionVariableSustained remission continued (*n* = 22)Flare (*n* = 7)*P* valueFemale, *n* (%)18 (81.9)6 (85.7)0.81Age, years49.8 ± 14.2 (52)54.4 ± 23.9 (63)0.33Weight, kg55.0 ± 9.5 (53)47.9 ± 8.3 (46)0.99Disease duration, years3.6 ± 4.5 (1.8)9.2 ± 11.3 (2)0.15Time until achievement of remission3.8 ± 3.3 (3)2.0 ± 1.9 (1)0.13DAS28-ESR at baseline3.97 ± 0.96 (3.73)4.19 ± 0.56 (4.13)0.41DAS28-ESR at achievement of remission1.85 ± 0.44 (1.96)2.25 ± 0.43 (2.42)0.027RF-positive, *n* (%)12 (54.6)4 (57.1)0.90ACPA-positive, *n* (%)13 (61.9)4 (66.7)0.83Presence of bone erosion, *n* (%)12 (57.1)5 (71.4)0.50HAQ-DI at baseline0.18 ± 0.36 (0)0.52 ± 1.11 (0)0.69HAQ-DI at achievement of remission0.23 ± 0.40 (0)0.54 ± 1.06 (0)0.76MTX at baseline, mg/week10.8 ± 3.01 (10)12.5 ± 3.45 (12.5)0.21MTX at achievement of remission, mg/week10.6 ± 2.79 (10)12.0 ± 3.00 (12)0.26Oral steroid use, *n* (%)3 (13.6)2 (28.6)0.36Prior use of biologics, *n* (%)3 (13.6)0 (0)0.30Observation period, months27.8 ± 18.6 (20.5)32.4 ± 21.4 (23.0)0.54Data are mean ± SD (median) unless otherwise indicated*DAS* disease activity score, *ESR* erythrocyte sedimentation rate, *RF* rheumatoid factor, *ACPA* anti-citrullinated protein antibody, *HAQ-DI* Health Assessment Questionnaire Disability Index, *MTX* methotrexateFig. 1The clinical course of patients who continued sustained remission and those who experienced RA flare. At all three points, disease activity were significantly reduced from baseline. (*P* value \< 0.0001, one-way ANOVA test)

Course of four patients who discontinued ADA because of sustained remission {#Sec10}
---------------------------------------------------------------------------

The characteristics of four patients who discontinued ADA because of sustained remission are summarized in Table [5](#Tab5){ref-type="table"}. Three of the four patients experienced RA flare after ADA discontinuation.Table 5Characteristics of four patients who discontinued ADA because of sustained remissionVariableCase 1Case 2Case 3Case 4SexFemaleFemaleFemaleFemaleAge, years38636980Weight, kg54425362Disease duration, years40.33.20.8DAS28-ESR at baseline4.345.924.094.96RF58\< 53580ACPA\> 100\< 0.659.2\> 300StageIIIIVIIHAQ-DI at baselineNo data1.6251.1250.75MTX mg/week8686Prior use of biologicsNoNoNoNoTime until achievement of remission, months11211Continuation of remission, months29121234DAS28-ESR at discontinuation of ADA0.972.111.462.50HAQ-DI at discontinuation of ADANo data0.7500First outcomeFlare at 6 monthsRemission continued for 29 monthsFlare at 8 monthsFlare at 3 monthsSecond outcomeAchieved remission 1 month after restarting ADANo flareNo remission after restarting ADAAchieved remission 1 month after restarting ADA*DAS* disease activity score, *ESR* erythrocyte sedimentation rate, *RF* rheumatoid factor, *ACPA* anti-citrullinated protein antibody, *HAQ-DI* Health Assessment Questionnaire Disability Index, *MTX* methotrexate

Discussion {#Sec11}
==========

We retrospectively identified factors that correlated with sustained remission and continuation of sustained remission. We found that sustained remission was associated with age, disease duration, DAS28-ESR and HAQ-DI at baseline, concomitant MTX, no concomitant prednisolone use, and no prior use of biologics. Continuation of sustained remission was associated with DAS28-ESR at the time of achievement of remission. A small number of RA patients discontinued ADA because of remission, with some experiencing a subsequent flare up.

Patients of the HONOR study \[[@CR9]\], an open-label, non-randomized study of Japanese patients with established RA and DAS28-ESR \< 2.6 for 6 months while under ADA treatment, had shorter disease duration, lower scores for patient global assessment and HAQ-DI, and lower ESR and DAS28-ESR. Further, the proportion of patients with DAS28-ESR \< 2.6 for 1 year was significantly lower (48%) in the ADA discontinuation group than in the ADA continuation group (83%) after remission was maintained for 6 months. Furthermore, reinitiating ADA resulted in the reinduction of low disease activity (LDA) by 90% within 6 months and 100% within 9 months without any harmful effects.

Our results concerning disease activity were similar to those of the HONOR study. Future studies should evaluate structural and functional remission. The HOPEFUL 2 study, a postmarketing observational study of early RA patients, demonstrated that 93% of patients among those with DAS28-CRP ≤ 2.0 at ADA discontinuation achieved sustained LDA for 1 year. This suggested that DAS28 remission might predict biologic-free disease control in patients with early RA \[[@CR10]\]. Further, 80% (12/15) of patients who discontinued ADA after achieving stable remission with ADA and MTX treatment had a flare up in the 6 months after discontinuation \[[@CR11]\].

In our study, 56% (22/39) of patients who achieved sustained remission for more than 6 months maintained sustained remission until the end of the observation period (mean ± SD, 27.8 ± 18.6 months; median, 20.5 months), and lower DAS28-ESR at the time of achievement of remission correlated with continuation of sustained remission. Among the patients who discontinued ADA after achieving sustained remission, 75% (3/4) experienced a flare up, and two of three patients achieved remission again 1 month after reinitiating ADA. Therefore, discontinuation of ADA after achieving remission should be decided with caution, with consideration given to the background of the patients.

In short-term sustained remission, no biologics history was a significant favorable factor (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). On the other hand, in long-term sustained remission, the number of prior use of biologics showed no significant difference between sustained remission continued and flare groups. In sustained remission continued group (*n* = 22), three cases had history of prior use of biologics (infliximab: 1, infliximab and etanercept: 2), whereas no history in flare group (*n* = 7). This discrepancy may be caused from the following possibilities. In later analysis, proportion of prior use of biologics was lower (3/29 vs 35/121) and statistical power may be insufficient. Furthermore, in sustained remission continued group may not be homogeneous. To clarify the difference of mode of action in biologics, analysis in further larger cohort is needed.

In HONOR study \[[@CR9]\], DAS28-ESR ≤ 1.98 was defined as "deep remission." In our cohort, mean and median DAS28-ESR at achievement of remission in sustained remission continued group were 1.85 and 1.96, whereas 2.25, 2.42 in flare group (Table [4](#Tab4){ref-type="table"}). Cut off value "1.98" of deep remission in HONOR study is comparable to our results. On the other hand, in four patients who discontinued ADA because of sustained remission, two patients with low DAS28-ESR (0.97 and 1.46) at achievement of remission flared at 6 and 8 months (Table [5](#Tab5){ref-type="table"}). We thought DAS28-ESR at achievement of remission was an important indicator for long-term sustained remission, but still unclear in discontinued ADA because of sustained remission.

Finally, we should note study limitation. Some of the patients reduced the dose of MTX or corticosteroid or may have elongated the treatment interval of ADA. Such treatment change might have affected the flare of disease.

Conclusion {#Sec12}
==========

Of 122 patients, 39 (32.0%) achieved remission that was sustained for more than 6 months and 22 of the 39 patients (56.4%) continued sustained remission until the end of the observation period. Continuation of sustained remission was correlated with DAS28-ESR at the time of achievement of remission.

ADA

:   Adalimumab

DAS28-ESR

:   28-Joint disease activity score with erythrocyte sedimentation rate

DMARDs

:   Disease-modifying antirheumatic drugs (DMARDs)

HAQ-DI

:   Health assessment questionnaire (HAQ-DI)

MTX

:   Methotrexate

RA

:   Rheumatoid arthritis

SD

:   Standard deviation
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